Press Releases July 29, 2026 08:00 AM

Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics schedules Q2 2026 earnings release and conference call

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
AKBA

Akebia Therapeutics plans to report its second quarter financial results for 2026 on August 5, 2026, with a subsequent conference call to discuss the results and recent business highlights. The company is a biopharmaceutical firm focused on kidney disease and is based in Cambridge, Massachusetts.

Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights
AKBA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Akebia Therapeutics will release Q2 2026 financial results on August 5, 2026.
  • A conference call to discuss financial results and business updates is scheduled for the same day.
  • Akebia is a biopharmaceutical company specializing in treatments for kidney disease.

CAMBRIDGE, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the second quarter ended June 30, 2026 on Wednesday, August 5, 2026, following the close of the financial markets.

Akebia will host a conference call on Wednesday, August 5, 2026, at 4:30 p.m. EDT to discuss its financial results and recent business highlights. To access the call, please dial (646) 307-1963 or toll-free (800) 715-9871 and enter passcode: 4727037. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time.

A live webcast of the conference call will be available via the Investors section of Akebia’s website at: https://ir.akebia.com/. An online archive of the webcast can be accessed via the Investors section of Akebia’s website at http://ir.akebia.com.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com


Risks

  • The article does not provide specific operational or financial performance updates, creating uncertainty about actual business momentum.
  • The competitive biotech sector and regulatory environment may impact future results, though no details are given in the release.
  • Market reaction may be influenced by the upcoming detailed financial disclosures and business highlights not outlined in this announcement.

More from Press Releases

MISSION SUCCESS: Rocket Lab Launches 96th Electron Mission Sep 19, 2026 FortuneX Acquisition Corporation and WT Realty Group Inc. Announce Business Combination Agreement Sep 18, 2026 XAI Floating Rate & Alternative Income Trust Announces Commencement of Tender Offer Sep 18, 2026 Greenland Mines Applauds Historic U.S.-Denmark-Greenland Security Agreement, Reinforcing Greenland’s Strategic Importance to the United States Sep 18, 2026 Home BancShares, Inc. Announces Recognition in Forbes Top-Performing Banks and Bank Director RankingBanking Sep 18, 2026